Dear Saxena ji,
Thank you for inquiry.
West facing windows can be a big source of heat, first measure which you...
Why all these are not applicable to Tuticorin port or the one planned in AP or WB ?
What an eye opener! As an environmental engineer,disposal of sanitary napkins has always been a concern during waste...
THE battle against the dreaded AlDs disease may yet be won. The Food and
Drug Administration in the us recently
approved a new class of drugs which
inhibits the ability of the HIV virus to
cause the disease. Manufactured by
Hoffman-La Roche Inc of Nutley in New
Jersey, the drug Sacluinavir, belongs to
the protease inhibitor group. Protease
is an important enzyme which aids the
reproduction of the HIV virus. The new
drug whose trade name is Invirase prevents the action of the enzyme and
thus suppresses the disease. A day's
dose of Invirase will cost US $15 89 and
includes 600 gm capsules to be taken
thrice a day.
Hoffman-La Roche promise to have
the drug on the pharmacy shelves in
the shortest possible time and have
also announced a financial assistance
programme for those who are unable
to afford the drug. The drug has minimal side effects, say its manufacturers.
It has also shown the ability to stop
the crucial immune system cells, called
CD-4 from declining in number and also
increase its count in some patients.
Further, it appears to reduce the total
amount of virus present in a patient's